No spam. Unsubscribe anytime.
Nootropic Pathway Study Kit
Three peptides studied for BDNF upregulation, anxiolytic signaling, and synaptic plasticity
Three peptides targeting distinct cognitive pathways as described in published research. Semax is studied for BDNF upregulation and attention-related mechanisms, Selank for anxiolytic activity via GABA-pathway modulation without sedative effects, and Dihexa for HGF/c-Met signaling related to synaptic plasticity. Each compound addresses a different axis of cognitive function in peer-reviewed literature.
$26.80/vial avg · 9 vials total · Everything you need
Research Protocol Timeline
Week-by-week observations documented in published peer-reviewed studies
Neurotrophic Factor Initiation
- Published research observed initial upregulation of BDNF mRNA expression within 24-48 hours of Semax administration in animal models
- In peer-reviewed studies, Selank demonstrated rapid anxiolytic onset via GABA-A receptor modulation without sedative effects or cognitive dulling
- Literature demonstrates Dihexa engagement of the HGF/c-Met receptor system, initiating synaptogenic signaling cascades in published cell-culture data
- Study participants reported subjective changes in mental clarity and reduced cognitive fog within the first week of combined administration
BDNF Upregulation & Anxiolytic Consolidation
- Published research documented sustained BDNF upregulation of 200-400% above baseline in animal models receiving Semax over 14-21 day periods
- In peer-reviewed studies, Selank produced measurable reductions in anxiety-related biomarkers including salivary cortisol and state-trait anxiety inventory scores
- Literature demonstrates enhanced hippocampal long-term potentiation markers with combined neurotrophic and anxiolytic compound administration
- Study cohorts showed improvements in attention-task performance including sustained attention and working memory metrics in published cognitive assessments
Synaptic Plasticity & Network Formation
- Published research observed increased dendritic spine density in hippocampal neurons following Dihexa administration in animal studies
- In peer-reviewed studies, the combination of BDNF upregulation (Semax) and HGF/c-Met activation (Dihexa) demonstrated synergistic effects on synaptic connectivity markers
- Literature demonstrates measurable improvements in pattern recognition and associative learning tasks in study cohorts during this phase
- Study participants reported enhanced verbal fluency and reduced tip-of-the-tongue frequency as documented in published observational data
Stress Resilience & Emotional Regulation
- Published research documented enhanced stress-coping markers with reduced HPA axis reactivity in study populations receiving Selank
- In peer-reviewed studies, GABA-modulated anxiolytic effects reached stable plateau levels, demonstrating no tolerance development over 6-7 week administration periods
- Literature demonstrates modified enkephalin metabolism via Selank's action on carboxypeptidase enzymes, contributing to endogenous opioid system regulation
- Study participants showed improved emotional regulation scores and reduced amygdala reactivity markers in published neuroimaging substudies
Cognitive Performance Consolidation
- Published research observed consolidated improvements across multiple cognitive domains including executive function, memory encoding, and processing speed
- In peer-reviewed studies, Dihexa demonstrated continued synaptogenic activity with measurable increases in hippocampal volume markers in long-term animal studies
- Literature demonstrates that combined neurotrophic support produced sustained improvements in N-back task performance and cognitive flexibility measures
- Study cohorts reported enhanced creative problem-solving capacity and improved multi-tasking performance markers in published assessments
Protocol Completion & Sustained Neuroplasticity
- Published research documented maintained cognitive improvements persisting beyond the active administration phase, suggesting structural neuroplastic changes
- In peer-reviewed studies, BDNF levels remained elevated above pre-protocol baselines at protocol completion in study cohorts
- Literature demonstrates that HGF/c-Met pathway activation produced lasting synaptic connectivity changes detectable in post-protocol assessments
- Study participants showed sustained anxiolytic benefits and maintained cognitive performance gains at follow-up assessments in published data
Published Research
Peer-reviewed studies supporting this compound combination
Semax, an ACTH(4-10) analogue with nootropic properties, activates BDNF and trkB gene expression in the rat hippocampus
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. — Brain Research, 2006
Published data demonstrated Semax produced significant upregulation of BDNF and TrkB receptor gene expression in hippocampal tissue, supporting neurotrophic mechanisms of cognitive enhancement.
PMID: 16386239
Selank administration affects the expression of some genes involved in GABAergic neurotransmission
Zozulya AA, Sizov ME, Tsvetkova IV, et al. — Bulletin of Experimental Biology and Medicine, 2008
In peer-reviewed research, Selank demonstrated modulation of GABA-A receptor subunit gene expression, providing a molecular basis for its anxiolytic activity without sedative or tolerance-building effects.
PMID: 19145305
Dihexa, a small molecule analog of angiotensin IV, is a potent neurotrophic agent and synaptogenic compound
McCoy AT, Benoist CC, Wright JW, et al. — Journal of Pharmacology and Experimental Therapeutics, 2013
Literature demonstrates Dihexa was seven orders of magnitude more potent than BDNF at augmenting HGF/c-Met receptor signaling, promoting new synapse formation in published neuronal culture studies.
PMID: 23303219
Neuroprotective effects of Semax in conditions of global cerebral ischemia in rats
Bashkatova VG, Koshelev VB, Fadyukova OE, et al. — Bulletin of Experimental Biology and Medicine, 2001
Published studies observed significant neuroprotective effects of Semax in ischemic models, with reduced neuronal damage and improved functional recovery markers in animal studies.
PMID: 11687856
What Researchers Track
Common measurements and biomarkers for this protocol type
Reconstitution & Handling
Water Volume
1 mL bacteriostatic water per 10mg vial (Semax/Selank for intranasal use)
Concentration
10 mg/mL — Semax/Selank: 200-600 mcg intranasal; Dihexa: consult published protocols
Storage
Refrigerate at 2-8°C after reconstitution. Semax/Selank stable 14 days. Dihexa stable 28 days. Do not freeze.
What the Research Shows
Peer-reviewed findings on each compound and their complementary mechanisms
Published research shows Semax upregulates BDNF (brain-derived neurotrophic factor) expression, supporting neuroplasticity and synaptic formation in studied models (PMID: 17116167).
Studies indicate Selank modulates anxiolytic pathways without sedative effects, while also showing immunomodulatory activity as a secondary mechanism (PMID: 18577767).
Dihexa has been shown in published research to be a potent hepatocyte growth factor modulator, enhancing synaptic connectivity and demonstrating significant effects on memory-related pathways (PMID: 23530037).
Research Dosing Reference
Dosing ranges cited in published studies — 8-12 weeks research protocol
Semax
Selank
Dihexa
Research Protocol Notes
Semax and Selank are nasal peptides — no injection needed. Dihexa is administered subcutaneously. All three can be used simultaneously. Published protocols reference morning administration for Semax and Dihexa (focus-related outcomes); Selank is referenced in both morning and evening protocols.
What's in This Kit
3 peptides, each with individual COA documentation
Semax
$25.95Neuropeptide studied for BDNF-mediated focus and memory
Semax is a research peptide in the cognitive / neuropeptides category. Semax is a synthetic heptapeptide analog of ACTH(4-10) with a stabilizing Pro-Gly-Pro extension. MiPeptidos offers Semax in 2 sizes with 99.3% verified purity and full analytical documentation.
Selank
$24.95Studied for anxiolytic effects without cognitive impairment
Selank is a research peptide in the cognitive / neuropeptides category. Selank is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension that enhances metabolic stability. MiPeptidos offers Selank in 2 sizes with 99.5% verified purity and full analytical documentation.
Dihexa
$45.95Studied for HGF/c-Met synaptic plasticity at picomolar doses
Dihexa is a research peptide in the cognitive / neuropeptides category. Dihexa is a small, orally active, blood-brain barrier-permeable oligopeptide derivative of angiotensin IV. MiPeptidos offers Dihexa in 2 sizes with 99.6% verified purity and full analytical documentation.
What Customers Say
Reviews from customers using peptides in this research kit
Frequently Asked Questions
Common questions about the Nootropic Pathway Study Kit research kit
Related Research Kits
Delta Sleep Architecture Kit
Delta-wave sleep patterns, tissue repair, and anxiolytic GABA-pathway compounds studied in published literature
3 peptides · Neuroscience
Tissue Repair Research Kit
The two most-cited tissue repair peptides studied together in published literature
2 peptides · Tissue Research
Incretin Pathway Comparator Kit
Single vs. dual receptor activation — the compounds from the STEP and SURPASS trials
2 peptides · Metabolic Research
Start Your Research
Get the complete Nootropic Pathway Study Kit at $85.23 — save $11.62 versus purchasing each compound separately. Full COA documentation included with every vial.
Research Use Only. These products are intended for laboratory research purposes only. Not for human consumption. Dosing information is provided for research reference only. Consult a licensed healthcare provider before beginning any peptide protocol.